These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38108937)

  • 1. Cuproptosis-Associated lncRNA Gene Signature Establishes New Prognostic Profile and Predicts Immunotherapy Response in Endometrial Carcinoma.
    Jiang XY; Hu JJ; Wang R; Zhang WY; Jin QQ; Yang YT; Mei J; Hong L; Yao H; Tao F; Li JJ; Liu Y; Zhang L; Chen SX; Chen G; Song Y; Zhou SG
    Biochem Genet; 2024 Oct; 62(5):3439-3466. PubMed ID: 38108937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
    Zhang X; Ye Z; Xiao G; He T
    Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.
    Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J
    Front Immunol; 2021; 12():788431. PubMed ID: 34970268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
    Chen Y
    Front Genet; 2022; 13():912037. PubMed ID: 35937995
    [No Abstract]   [Full Text] [Related]  

  • 5. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma.
    Liu B; Liu Z; Feng C; Li C; Zhang H; Li Z; Tu C; He S
    Front Endocrinol (Lausanne); 2022; 13():987942. PubMed ID: 36313774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
    Wang S; Bai H; Fei S; Miao B
    Biochem Genet; 2024 Jun; 62(3):2332-2351. PubMed ID: 37898914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer.
    Wang L; Xiao K; Dong Z; Meng T; Cheng X; Xu Y
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10543-10559. PubMed ID: 37291405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel lncRNA-focus expression signature for survival prediction in endometrial carcinoma.
    Zhou M; Zhang Z; Zhao H; Bao S; Sun J
    BMC Cancer; 2018 Jan; 18(1):39. PubMed ID: 29304762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated Identification and Immunotherapy Response Analysis of the Prognostic Signature Associated With m6A, Cuproptosis-Related, Ferroptosis-Related lncRNA in Endometrial Cancer.
    Qian Y; Chen H; Miao P; Ma R; Lu B; Hu C; Fan R; Xu B; Chen B
    Cancer Rep (Hoboken); 2024 Sep; 7(9):e70009. PubMed ID: 39324703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of an Immune-Related LncRNA Prognostic Signature in Uterine Corpus Endometrial Carcinoma Patients.
    Sun XX; Wen HQ; Zhan BX; Yang P
    Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
    Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
    Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 7-lncRNA signature predict prognosis of Uterine corpus endometrial carcinoma.
    Ouyang D; Li R; Li Y; Zhu X
    J Cell Biochem; 2019 Oct; 120(10):18465-18477. PubMed ID: 31168849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and verification of a newly established cuproptosis-associated lncRNA model for predicting overall survival in uterine corpus endometrial carcinoma.
    Hu P; Wang Y; Chen X; Zhao L; Qi C; Jiang G
    Transl Cancer Res; 2023 Aug; 12(8):1963-1979. PubMed ID: 37701111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying immune subtypes of uterine corpus endometrial carcinoma and a four-paired-lncRNA signature with immune-related lncRNAs.
    Li N; Yu K; Lin Z; Zeng D
    Exp Biol Med (Maywood); 2022 Feb; 247(3):221-236. PubMed ID: 34704492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
    Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing four cuproptosis-related lncRNAs signature to predict prognosis and immune activity in ovarian cancer.
    Liu L; Wang Q; Zhou JY; Zhang B
    J Ovarian Res; 2023 Apr; 16(1):88. PubMed ID: 37122030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
    Huang Y; Gong P; Su L; Zhang M
    Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of cuproptosis-related lncRNA signatures for prognosis prediction in colorectal cancer.
    Pang L; Wang Q; Wang L; Hu Z; Yang C; Li Y; Wang Z; Li Y
    BMC Med Genomics; 2023 Mar; 16(1):58. PubMed ID: 36949429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment and validation of a cuproptosis-related lncRNA signature that predicts prognosis and potential targeted therapy in hepatocellular carcinoma.
    Guo DF; Fan LW; Zeng HH; Huang CB; Wu XH
    Biotechnol Genet Eng Rev; 2024 Oct; 40(2):739-764. PubMed ID: 36951200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.